The pharma company behind Wegovy and what it means for your treatment

The biggest mix-up: Wegovy, Ozempic, and Rybelsus are not the same product

It is genuinely one of the questions our prescribers field most weeks: if Ozempic and Wegovy both contain semaglutide, why does it matter which one you ask about? The answer sits in the licence, not the molecule. Novo Nordisk developed semaglutide first as a diabetes treatment, running large trials under the SCALE and SUSTAIN programmes before recognising that the same compound, at higher doses, produced clinically meaningful weight loss in people without diabetes.

That observation led to a separate development programme, separate clinical trials, a separate marketing authorisation from the MHRA, and a separate product name: Wegovy. The weight-management dose reached 2.4 mg weekly, well above the doses used in Ozempic. Rybelsus, meanwhile, is oral semaglutide in tablet form, also licensed for type 2 diabetes at doses of 3 mg, 7 mg and 14 mg — those strengths have nothing to do with the Wegovy tablet ladder, which runs from 1.5 mg up to 25 mg at maintenance.

Prescribers in the UK can only issue a medicine for its licensed indication. That is why someone seeking weight management treatment will be prescribed Wegovy, not Ozempic, even though the molecules look identical under a microscope. Wegovy's UK licensing history explains this in more depth if you want the full regulatory picture.

Novo Nordisk's role: manufacturer, licence holder, and supply-chain anchor

Novo Nordisk holds the UK marketing authorisation for Wegovy, which means the company is legally responsible for the product's quality, safety monitoring, and supply. The company manufactures semaglutide at its own production sites and distributes to authorised wholesalers, who in turn supply GPhC-registered pharmacies. That chain matters because it is the mechanism that keeps a medicine genuine: every pen that moves through the licensed route carries batch traceability back to the manufacturer.

The MHRA has made clear that semaglutide pens sold outside the licensed supply chain (through social media sellers or websites that do not ask for a clinical assessment) cannot be verified as genuine. Novo Nordisk does not sell directly to individuals, and no legitimate UK pharmacy sources its stock outside that authorised chain. If a seller cannot point you to their GPhC registration, that is reason enough to pause.

Novo Nordisk has expanded Wegovy's approved forms as evidence accumulates. The MHRA approved a higher 7.2 mg dose in January 2026, and on 14 April 2026 approved a dedicated single-dose 7.2 mg pen designed for weekly self-injection. In July 2026 the regulator granted a further approval for semaglutide as a treatment for a form of fatty liver disease (MASH), adding a third licensed indication to the company's semaglutide portfolio, though Wegovy at nume is prescribed for weight management specifically.

What the STEP trials mean for patients, and what Novo Nordisk's data actually shows

Novo Nordisk conducted the STEP clinical trial programme to support Wegovy's weight-management licence. The flagship study, STEP 1, published in the New England Journal of Medicine, followed adults with obesity or overweight plus at least one weight-related condition over 68 weeks. Participants receiving 2.4 mg semaglutide alongside lifestyle changes achieved around 15% average body-weight reduction, a figure that, at the time, was among the largest seen in a randomised controlled trial for a non-surgical intervention.

Since then, Novo Nordisk has run further trials at the 7.2 mg dose, reporting around 20.7% average weight loss over 72 weeks. That puts the higher dose closer in effect size to tirzepatide's results, narrowing a gap that had previously distinguished the two available treatments. NICE's appraisal of semaglutide (TA875) reviewed the STEP evidence before recommending Wegovy for use within specialist NHS weight management services, subject to specific eligibility criteria and a maximum duration of two years.

None of that means Wegovy is automatically the right choice for every individual. Tirzepatide, which works on two receptor pathways rather than one, has shown larger average losses in head-to-head data. Which medicine suits a particular person depends on their medical history, other medicines, existing conditions, and what their prescriber considers appropriate after a full clinical assessment. Check your eligibility to see which treatments our prescribers could review for you.

How Novo Nordisk's supply situation affects private patients in the UK

Demand for Wegovy has outpaced supply in several markets since the medicine gained widespread attention. Novo Nordisk has invested significantly in manufacturing capacity and the UK supply situation has improved, but it is worth understanding how the licensed chain works for anyone accessing treatment privately.

A GPhC-registered pharmacy sources its Wegovy stock from authorised UK wholesalers operating within the MHRA-regulated supply chain. If a particular pen or dose is temporarily low in stock, a legitimate pharmacy will tell you clearly and advise on next steps rather than substituting an unlicensed alternative. At our pharmacy, every order is reviewed by a named prescriber before dispatch, and stock availability is confirmed at the point of clinical review. For a fuller look at what private treatment typically costs and what a quoted price should include, the Wegovy cost guide runs through the components honestly.

If you are curious about how the Wegovy company is structured and what its responsibilities are as a licence holder, or about what the drug company behind Wegovy has meant for price and supply, more background on the pharma landscape behind semaglutide covers that ground. The short version: two large, well-resourced companies making competing products has generally been good for investment in new formulations, and the arrival of the oral semaglutide tablet, which represents a significant step in wegovy pharma development, in June 2026 is the clearest example of that.